Hvivo (HVO)

Sector:

Health Care

Index:

FTSE AIM All-Share

28.50p
   
  • Change Today:
      0.60p
  • 52 Week High: 30.60
  • 52 Week Low: 18.00
  • Currency: UK Pounds
  • Shares Issued: 680.37m
  • Volume: 1,724,303
  • Market Cap: £193.91m

Open Orphan signs ?3.5m deal with US biotech firm

By Josh White

Date: Monday 04 May 2020

LONDON (ShareCast) - (Sharecast News) - Pharmaceutical services company Open Orphan announced the signing of a new contract with an unnamed US biotechnology company on Monday, for the provision of a respiratory syncytial virus (RSV) human challenge study.
The AIM-traded firm said the challenge study was projected to deliver ?3.5m in revenue in 2020.

It said that it would use the complementary in-house clinical research organisation services of hVIVO and Venn Life Sciences, following the completion of the merger with hVIVO.

Open Orphan also announced that Trevor Phillips would stand down as its chief executive officer.

The board said a "strong" management team was in place, with Cathal Friel continuing as executive chairman, running the business alongside a leadership team focussed on delivering growth.

"The signing of this new ?3.5m contract with a US biotechnology Company is further evidence of this exciting time as we successfully convert Open Orphan's pipeline of prospects into formal customer contracts," said Cathal Friel.

"Open Orphan will be utilising its complementary in-house clinical research organisation services of hVIVO and Venn to deliver this contract.

"This contract demonstrates the Open Orphan and hVIVO group's focus on building long term contracts with recurring revenues to deliver future profitability while ensuring rationalising the business and reducing costs."

At 1615 BST, shares in Open Orphan were up 9.64% at 9.87p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Hvivo Market Data

Currency UK Pounds
Share Price 28.50p
Change Today 0.60p
% Change 2.15 %
52 Week High 30.60
52 Week Low 18.00
Volume 1,724,303
Shares Issued 680.37m
Market Cap £193.91m

Hvivo Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
95.74% below the market average95.74% below the market average95.74% below the market average95.74% below the market average95.74% below the market average
65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average
Price Trend
78.19% above the market average78.19% above the market average78.19% above the market average78.19% above the market average78.19% above the market average
94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average
Income
94.38% below the market average94.38% below the market average94.38% below the market average94.38% below the market average94.38% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
52.34% above the market average52.34% above the market average52.34% above the market average52.34% above the market average52.34% above the market average
72.22% above the sector average72.22% above the sector average72.22% above the sector average72.22% above the sector average72.22% above the sector average

What The Brokers Say

Strong Buy 3
Buy 3
Neutral 0
Sell 0
Strong Sell 0
Total 6
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Hvivo Dividends

  Latest Previous
  Final Special
Ex-Div 18-Apr-24 04-May-23
Paid 20-May-24 09-Jun-23
Amount 0.20p 0.45p

Trades for 31-Oct-2024

Time Volume / Share Price
16:37 275 @ 28.50p
16:20 71,610 @ 28.25p
16:16 7,150 @ 28.40p
15:56 3,469 @ 28.65p
14:48 150,000 @ 28.15p

Hvivo Key Personnel

CEO Yamin Mo' Khan

Top of Page